Valeant Discounts Will Save Health Care System $600M Annually, Firm Says
This article was originally published in The Pink Sheet Daily
In a direct distribution agreement with Walgreens, Valeant, often the focus of criticism over high drug prices, will cut prices 10% on branded dermatology and ophthalmology products and an average of over 50% on certain branded products with generic competition.
You may also be interested in...
Probe launched by the Senate Aging panel asks four manufacturers – Valeant, Turing, Retrophin and Rodelis – for documents pertaining to pricing their products, but also wants to know how they may have analyzed FDA regs to help them avoid competition.
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.